RET and lung adenocarcinoma: The KIF5B-RET fusion led to aberrant activation of RET kinase and is considered to be a new driver mutation of lung adenocarcinoma because it segregates from mutations or fusions in EGFR, KRAS, HER2, and ALK. Additionally, RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells [21].